To further determine the role of SHP2 in promoting vemurafenib resistance, we treated BRAFV600E mutant thyroid cancer cell resistant strains (BCPAP-R and K-1-R) with DMSO, vemurafenib, SHP099, and the combination of vemurafenib and SHP099. The gene discussed is PTPN11; the disease is thyroid gland carcinoma.